Objective To report a case of fungal keratitis caused by plant pathogens,evidenced by laboratory testing.Methods Specimens were collected by corneal scraping from a 52-year-old male patient for pathogen culture.The patient was treated at Qionghai People's Hospital for fungal keratitis.The isolates were identified and tested for antimicrobial susceptibility.PubMed,CNKI,Wanfang,and VIP database were searched using keywords Diaporthe or Diaporthe phaseolorum in English and Chinese from the establishment of the database to December 10,2024.A retrospective literature review was conducted on the cases of human infection caused by Diaporthe.Results The specimens from corneal scraping were directly examined under a microscope.Septate fungal hyphae were observed.The isolate was identified as Diaporthe phaseolorum by targeted DNA sequencing.Antimicrobial susceptibility testing by microdilution method showed that the minimum inhibitory concentrations(MIC)of fluorocytosine,fluconazole,amphotericin B,voriconazole,itraconazole,posaconazole,micafungin,caspofungin,and anidulafungin against this strain were＞64,64,0.5,0.12,2,0.06,0.03,＜0.03,and 0.12 mg/L,respectively.Clinicians adjusted the antifungal treatment plan timely based on the antimicrobial susceptibility testing results.The patient's vision was restored.Literature review found that of the 12 reported cases of infection worldwide,6 were localized skin or soft tissue infections,3 were peritonitis,and the remaining 3 cases were keratitis.Overall,9 patients were immunocompromised and 3 had normal immune function.Human infections caused by Diaporthe often occur in immunocompromised individuals.Invasive infections often lead to patient mortality.There are no established breakpoints for common antifungal agents against Diaporthe.The MICs against the strain were higher for flucytosine and fluconazole,but lower for azoles,echinocandins,and polyenes.Conclusions Fungal keratitis caused by D.phaseolorum is an emerging infection.The information in this case,including clinical symptoms,the morphology of D.phaseolorum under microscope after corneal scraping,the growth characteristics and antifungal susceptibility testing,targeted DNA sequencing,can inform the microbiology laboratory staff and clinicians of D.phaseolorum infections in the future.

Objective To report a case of fungal keratitis caused by plant pathogens,evidenced by laboratory testing.Methods Specimens were collected by corneal scraping from a 52-year-old male patient for pathogen culture.The patient was treated at Qionghai People's Hospital for fungal keratitis.The isolates were identified and tested for antimicrobial susceptibility.PubMed,CNKI,Wanfang,and VIP database were searched using keywords Diaporthe or Diaporthe phaseolorum in English and Chinese from the establishment of the database to December 10,2024.A retrospective literature review was conducted on the cases of human infection caused by Diaporthe.Results The specimens from corneal scraping were directly examined under a microscope.Septate fungal hyphae were observed.The isolate was identified as Diaporthe phaseolorum by targeted DNA sequencing.Antimicrobial susceptibility testing by microdilution method showed that the minimum inhibitory concentrations(MIC)of fluorocytosine,fluconazole,amphotericin B,voriconazole,itraconazole,posaconazole,micafungin,caspofungin,and anidulafungin against this strain were＞64,64,0.5,0.12,2,0.06,0.03,＜0.03,and 0.12 mg/L,respectively.Clinicians adjusted the antifungal treatment plan timely based on the antimicrobial susceptibility testing results.The patient's vision was restored.Literature review found that of the 12 reported cases of infection worldwide,6 were localized skin or soft tissue infections,3 were peritonitis,and the remaining 3 cases were keratitis.Overall,9 patients were immunocompromised and 3 had normal immune function.Human infections caused by Diaporthe often occur in immunocompromised individuals.Invasive infections often lead to patient mortality.There are no established breakpoints for common antifungal agents against Diaporthe.The MICs against the strain were higher for flucytosine and fluconazole,but lower for azoles,echinocandins,and polyenes.Conclusions Fungal keratitis caused by D.phaseolorum is an emerging infection.The information in this case,including clinical symptoms,the morphology of D.phaseolorum under microscope after corneal scraping,the growth characteristics and antifungal susceptibility testing,targeted DNA sequencing,can inform the microbiology laboratory staff and clinicians of D.phaseolorum infections in the future.

OBJECTIVE: To assess the value of chromosomal microarray analysis (CMA) for the detection of low-level mosaicisms in amniotic fluid samples, and to retrospectively analyze the rare cases of mosaicisms. METHODS: Chromosomal karyotype of the fetus was determined by G-banding analysis of cultured amniotic fluid cells. CMA was used to detect copy number variation of fetal chromosomes, and fluorescence in situ hybridization (FISH) was used to determine the proportion of fetal chromosomal mosaicisms in uncultured amniotic fluid cells. RESULTS: Among 825 prenatal samples, 4 cases of true fetal mosaicisms were detected, which yielded an incidence of 0.48%. Two cases were sex chromosomal mosaicisms, and two were autosomal mosaicisms, which involved chromosomes 8 and 9, respectively. All cases were verified by G-banding analysis of cultured amniotic fluid cells, CMA, and/or FISH. CONCLUSION CMA has a great value for detecting low-level mosaicisms in amniotic fluid samples, though the positive results need to be verified by other techniques and should be interpreted with caution. The review of rare cases can provide a basis for prenatal genetic counseling.
Humans ; Female ; Amniotic Fluid/metabolism* ; Pregnancy ; Mosaicism/embryology* ; Prenatal Diagnosis/methods* ; Adult ; In Situ Hybridization, Fluorescence ; Microarray Analysis/methods* ; Karyotyping ; Retrospective Studies ; Male

Objective To investigate the correlation between peripheral blood syndecan-1(SDC-1)and ma-londialdehyde-modified low-density lipoprotein(MDA-LDL)with arteriosclerosis(AS)in hemodialysis pa-tients and their clinical predictive value.Methods A total of 125 hemodialysis patients admitted to the hospi-tal from January 2022 to June 2024 as the hemodialysis group,and 65 healthy individuals who underwent physical examination during the same period as the control group.According to whether AS occurred,hemodi-alysis patients were divided into AS group(65 cases)and non-AS group(60 cases).The levels of SDC-1 and MDA-LDL in peripheral blood were detected by enzyme-linked immunosorbent assay.The correlation between the levels of SDC-1 and MDA-LDL in peripheral blood of hemodialysis patients and brachial-ankle pulse wave velocity(baPWV)was analyzed by Spearman correlation analysis.Multivariate unconditional Logistic regres-sion was used to determine the relationship between the levels of SDC-1 and MDA-LDL in peripheral blood and AS in hemodialysis patients.The receiver operating characteristic(ROC)curve was used to analyze the pre-dictive efficacy of peripheral blood SDC-1 and MDA-LDL levels for AS in hemodialysis patients.Results Compared with the control group,the levels of SDC-1 and MDA-LDL in the peripheral blood of the hemodialysis group increased(P＜0.05).The levels of SDC-1 and MDA-LDL in the peripheral blood of hemodialysis patients were positively correlated with left baPWV and right baPWV(P＜0.05).High SDC-1 and high MDA-LDL were both independent risk factors for AS in hemodialysis patients(P＜0.05).The area under the curve for the combined prediction of AS in hemodialysis patients by peripheral blood SDC-1 and MDA-LDL levels was 0.858,which was greater than 0.785 and 0.778 predicted separately by peripheral blood SDC-1 and MDA-LDL levels(P＜0.05).Conclusion The increase of SDC-1 and MDA-LDL levels in peripheral blood of hemodialy-sis patients is closely related to AS,and the combination of SDC-1 and MDA-LDL levels in peripheral blood has a higher energy efficiency in predicting AS.

Objective:To investigate the clinical efficacy and safety of the triplet regimen of flumatinib, venetoclax (VEN) and azacitidine (AZA) for Philadelphia chromosome-positive (Ph +) mixed-phenotype acute leukemia (MPAL). Methods:The clinical data of 2 Ph + MPAL patients treated with triplet regimen of flumatinib, VEN and AZA who were admitted to the Institute of Hematology & Blood Diseases Hospital of Chinese Academy of Medical Sciences & Peking Union Medical College in February and March 2023 were retrospectively analyzed, and the relevant literature was reviewed. Results:Patient 1 was a 56-year-old female, and patient 2 was a 59-year-old male. Both patients were diagnosed with Ph + B cell/myeloid (B/My) MPAL. After the first course of induction chemotherapy with the triplet regimen, patient 1 achieved hematological complete remission (HCR), complete cytogenetic remission (CCyR) and major molecular response (MMR), and patient 2 achieved HCR and CCyR. During the entire treatment process, the adverse reactions of two patients were mainly fever and ≥ grade 3 hematological adverse reactions, which were relieved after the use of antibiotics and intermittent infusion of blood products. When the patient achieved HCR and received consolidation treatment with the same regimen, the adverse reactions were mild. Conclusions:The triplet regimen of flumatinib, VEN and AZA is safe and effective for the treatment of Ph + MPAL, and is a new induction therapy option for such patients.

Objective:To assess the value of chromosomal microarray analysis (CMA) for the detection of low-level mosaicisms in amniotic fluid samples, and to retrospectively analyze the rare cases of mosaicisms.Methods:Chromosomal karyotype of the fetus was determined by G-banding analysis of cultured amniotic fluid cells. CMA was used to detect copy number variation of fetal chromosomes, and fluorescence in situ hybridization (FISH) was used to determine the proportion of fetal chromosomal mosaicisms in uncultured amniotic fluid cells. Results:Among 825 prenatal samples, 4 cases of true fetal mosaicisms were detected, which yielded an incidence of 0.48%. Two cases were sex chromosomal mosaicisms, and two were autosomal mosaicisms, which involved chromosomes 8 and 9, respectively. All cases were verified by G-banding analysis of cultured amniotic fluid cells, CMA, and/or FISH.Conclusion:CMA has a great value for detecting low-level mosaicisms in amniotic fluid samples, though the positive results need to be verified by other techniques and should be interpreted with caution. The review of rare cases can provide a basis for prenatal genetic counseling.

Objective:To assess the value of chromosomal microarray analysis (CMA) for the detection of low-level mosaicisms in amniotic fluid samples, and to retrospectively analyze the rare cases of mosaicisms.Methods:Chromosomal karyotype of the fetus was determined by G-banding analysis of cultured amniotic fluid cells. CMA was used to detect copy number variation of fetal chromosomes, and fluorescence in situ hybridization (FISH) was used to determine the proportion of fetal chromosomal mosaicisms in uncultured amniotic fluid cells. Results:Among 825 prenatal samples, 4 cases of true fetal mosaicisms were detected, which yielded an incidence of 0.48%. Two cases were sex chromosomal mosaicisms, and two were autosomal mosaicisms, which involved chromosomes 8 and 9, respectively. All cases were verified by G-banding analysis of cultured amniotic fluid cells, CMA, and/or FISH.Conclusion:CMA has a great value for detecting low-level mosaicisms in amniotic fluid samples, though the positive results need to be verified by other techniques and should be interpreted with caution. The review of rare cases can provide a basis for prenatal genetic counseling.

OBJECTIVE To establish a method for the determination of the concentrations of anti-tumor lead compounds purine benzamides PLB-E and PLB-P in rat plasma by HPLC and apply to study pharmacokinetics. METHODS The established HPLC was used to determine the plasma drug concentrations of rats at different time points after intravenous administration of 5, 10, 20 mg·kg–1 (low, medium, high doses) of PLB-E and PLB-P, and the pharmacokinetic parameters of each compound were calculated using DAS 3.3.0 software. RESULTS PLB-E and PLB-P had good linear relationship in the range of 2–120, 3–60 μg·mL–1, respectively(r2>0.999). The RSD of inter-day and intra-day precision were <15%. The extraction recoveries were 87.48%–92.84% and 88.24%–92.60%, respectively. The main pharmacokinetic parameters of PLB-E and PLB-P after a single intravenous injection of 5, 10, 20 mg·kg–1 were as follows, the average Cmax was (20.30±2.39), (40.63±3.40), (63.62±7.55)mg·L–1 and (13.21±1.40), (24.87±1.33), (32.83±0.65)mg·L–1, respectively. AUC(0-∞) were (104.67±48.39), (177.42±84.11), (194.32±91.48)mg·h·L–1 and (106.75±54.21), (179.90±93.59), (253.56±126.17)mg·h·L–1, respectively. Tmax of each dose was 0.08 h. CONCLUSION The HPLC method established in this study meets the requirements for the determination of biological samples through methodological verification, which is applicable to the determination of the concentration of PLB-E and PLB-P in rat plasma and the pharmacokinetic study. The pharmacokinetic process of PLB-E and PLB-P in rats conforms to the two-compartment model, and conforms to the nonlinear kinetic elimination.

OBJECTIVE To optimize the honey processing technology of Phellinus igniarius. METHODS The key factors of honey processing technology of P. igniarius （honey-water ratio， the mass ratio of honey-water to P. igniarius， the frying temperature and the frying time） were investigated by orthogonal test combined with analytic hierarchy process to determine the optimal technological parameters， using the internal quality （the contents of ergosterol， protocatechuic aldehyde and protocatechuic acid） and appearance traits as evaluation indexes. RESULTS The optimal process of honey-roasting P. igniarius was to take raw P. igniarius （1 cm3 square block）， add the appropriate amount of auxiliary materials （with 25 kg of refined honey and water for every 100 kg of P. igniarius）， mix well， moisten for 2 h until the auxiliary materials were completely absorbed； put it in a frying container， fry at the frying temperature of 130-140 ℃ for 5 min； take it out， put it in an oven at 50 ℃ for 2 h； take it out， and let it cool. The RSD of the results of three validation experiments was 0.68%. CONCLUSIONS The optimized honey processing technology of P. igniarius is stable and feasible.

OBJECTIVE To optimize the honey processing technology of Phellinus igniarius. METHODS The key factors of honey processing technology of P. igniarius （honey-water ratio， the mass ratio of honey-water to P. igniarius， the frying temperature and the frying time） were investigated by orthogonal test combined with analytic hierarchy process to determine the optimal technological parameters， using the internal quality （the contents of ergosterol， protocatechuic aldehyde and protocatechuic acid） and appearance traits as evaluation indexes. RESULTS The optimal process of honey-roasting P. igniarius was to take raw P. igniarius （1 cm3 square block）， add the appropriate amount of auxiliary materials （with 25 kg of refined honey and water for every 100 kg of P. igniarius）， mix well， moisten for 2 h until the auxiliary materials were completely absorbed； put it in a frying container， fry at the frying temperature of 130-140 ℃ for 5 min； take it out， put it in an oven at 50 ℃ for 2 h； take it out， and let it cool. The RSD of the results of three validation experiments was 0.68%. CONCLUSIONS The optimized honey processing technology of P. igniarius is stable and feasible.